About

Chris Martin has served as an Achieve Life Sciences director since 2026, chairing the Commercial Committee and serving on the Compensation Committee. He served as Chief Commercial Officer of Verona Pharma from January 2024 to October 2025 (when Verona was acquired by Merck & Co.), having earlier been its Senior Vice President and Vice President of Commercial. Before Verona he was Executive Director of Marketing at SK Life Science (2018-2020), Head of Marketing at Cempra (until its acquisition by Melinta Therapeutics), and spent ten years at Salix Pharmaceuticals. Mr. Martin also serves on the boards of Oruka Therapeutics (since 2025) and Edgewise Therapeutics (since 2025) and received a Bachelor of Science in Financial Management from Clemson University.

Roles

Achieve Life Sciences, Inc.
Director (Chair, Commercial Committee) · Current role
2026–present
Verona Pharma
Chief Commercial Officer · Acquired by Merck & Co. in October 2025
2024 - 2025
Verona Pharma
SVP / VP of Commercial
2020 - 2023
SK Life Science
Executive Director of Marketing
2018 - 2020
Cempra
Head of Marketing
Salix Pharmaceuticals
Roles of increasing responsibility · 10 years

External Roles

Oruka Therapeutics
Director
2025 - present
Edgewise Therapeutics, Inc.
Director
2025 - present

Also at Achieve Life Sciences, Inc.

Related

See how VectorShift works for your firm

Request Demo